Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus.
10.4093/dmj.2016.40.5.339
- Author:
Sung Ho KIM
1
;
Jung Hwa YOO
;
Woo Je LEE
;
Cheol Young PARK
Author Information
1. LG Life Sciences Ltd., R&D Park, Daejeon, Korea.
- Publication Type:Review
- Keywords:
Diabetes mellitus, type 2;
Dipeptidyl-peptidase IV inhibitors;
LC15-0444
- MeSH:
Biological Science Disciplines;
Diabetes Mellitus, Type 2*;
Dipeptidyl-Peptidase IV Inhibitors;
Glucagon;
Hyperglycemia;
Incretins;
Insulin;
Patient Compliance;
Pharmacology
- From:Diabetes & Metabolism Journal
2016;40(5):339-353
- CountryRepublic of Korea
- Language:English
-
Abstract:
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antidiabetic agent for the treatment of type 2 diabetes mellitus. They increase endogenous levels of incretin hormones, which stimulate glucose-dependent insulin secretion, decrease glucagon secretion, and contribute to reducing postprandial hyperglycemia. Although DPP-4 inhibitors have similar benefits, they can be differentiated in terms of their chemical structure, pharmacology, efficacy and safety profiles, and clinical considerations. Gemigliptin (brand name: Zemiglo), developed by LG Life Sciences, is a potent, selective, competitive, and long acting DPP-4 inhibitor. Various studies have shown that gemigliptin is an optimized DPP-4 inhibitor in terms of efficacy, safety, and patient compliance for treatment of type 2 diabetes mellitus. In this review, we summarize the characteristics of gemigliptin and discuss its potential benefits in clinical practice.
